We describe a sensitive, specific liquid-chromatographic determination of penbutolol and its 4-hydroxy metabolite in plasma and urine. The method involves a simple organic extraction, evaporation of the solvent, reconstitution in methanol/water, and injection into the chromatograph. Penbutolol, its metabolites, and the internal standard, propranolol, are resolved on a CN reversed-phase column and detected fluorometrically. Conjugates of penbutolol and its 4-hydroxy metabolite may be determined after a 2-h enzymic hydrolysis. Detection limits are in the range of 3 to 12 g/L of plasma. The assay is reproducible and nearly free of interferences. Representative concentrations in blood and urine of normal volunteers are reported.
and ( emission spectra, excited at 275 nm, for (-..-) penbutolol 1 pg/mL, ( . -) 4.. Assay urine samples as describedfor total drugs in plasma.
Patient protocol. The subjects were ostensibly healthy male volunteers, ages 21 to 50, weighing within 10% of their desirable weight. No other medication was allowed for a week before or during this study. The 40-mg drug tablet (CT-5825-2A) was administered with 200 mL of water, after the subject had fasted overnight. A standard breakfast was allowed 3 h after dosing. Blood was sampled into heparintreated Vacutainer Tubes (7) at appropriate intervals. The plasma was promptly separated and stored at -20 #{176}C (or -70 #{176}C when available) until assayed. Urine samples were collected before dosing and 2, 4, 8, 12, 24, 48, 72, 96 , and 120 h after dosing, and similarly stored.
Identity of conjugates. We used a glucuronidase inhibitor, saccharic acid 1,4-lactone, to investigate the identity of the conjugates of penbutolol and 4-hydroxypenbutolol. Two plasma specimens were used from each of eight persons, four of whom were the normal volunteers described above and four of whom were hypertensive patients receiving 80-or 120-mg daily doses of penbutolol sulfate. The specimens chosenwere all drawn between 1 and 4 h after dosing. Three 0.3-mL portions of each of the 16 samples were transferred to separate tubes. To one we added acetate buffer only, the second received acetate bufler containing glucuronidase, and the third received 4 mg of inhibitor first, followedby acetate buffer/glucuronidase.
All were then hydrolyzed as described above (in the presence of bisulfite), extracted, and injected.
Results

Assay Variables
Fluorescence. Our initial chromatographic examination of plasma sample extracts with ultraviolet detectionat 271 nm indicated that the detection limit for such an approach would be about 50 ng of penbutolol per milliliter of plasma. Hadju and Damm (3) had previously reported the fluorescenceof penbutolol, so we investigated this means of detecting penbutolol, its 4-hydroxy metabolite, and propranolol (the internal standard). Figure 1 shows the spectra for the three compounds in mobile phase, together with a background scan. The spectrum for penbutolol approximates that previously reported (3). The spectra for 4-hydroxypenbutolol and propranolol, which are similar to each other, are red-shifted relative to penbutolol. lengths and slit widths is a Raman band of the solvent, which occurs with a shift of roughly 29 nm. A brief study of the influence of emission wavelength and slit width, with settings of 275 nm and 6 nm for excitation, on the signal/ noise ratio for the three compounds indicated that 324 mm, with 10-nm slit width,would be nearly optimum.
Extraction. Methods previously reported for determination of penbutolol generally have involved adding strong base to the sample before extraction.
To 
Chromatography.
The chromatography of these compounds was initially investigated on conventional octylsilane (C8) bonded phase columns, but these did not resolve the peaks for these compounds from interfering peaks. Addition of ion-pairing reagents such as heptyl or octyl sulfonate, 5-10 mmoLIL, enhanced the retention of the catijnic analytes relative to background peaks. However, the retention of penbutolol became inconveniently long relative to that of 4-hydroxypenbutolol, as has been observed before (6) . Analogous enhancement of compound retentionrelative to background peaks was achieved through use of a cyano (CN) column. Relatively good peak shapes and resolutionof the compounds from the majority of interferences resulted when we used animonium acetate in methanolJwater as a mobile phase. In addition, the three compoundseluted near each other. Column lifetime has been several months, even with continual use. We included a small amount of tetrahydrofuran in the mobile phase to ensure resolution of 4-hydroxypenbutolol from a small peak originatingfrom Glusulase. Figure 2 shows representative chromatograms.
After some anomalies were noted, we investigated the effect of variousinjection solvents on the chromatography of the three compounds. Not surprisingly, given the ion-exchange character of the retention of these compounds, the pH of the injected sample profoundly affected the chromatographic results. As the pH of the injected sample (in mobile phase) was increased above the pH of the mobile phase, the retention times for all three compounds increased. If the pH was lowered relative to the mobile phase, their retention times decreased. Thus we chose the pH of the mobile phase to be close to the piCa of acetic acid to provide buffering capacity. Peak shapes were also dramatically affected when the compounds were injected in solutions enriched in methanol (>800 mL/L). To prevent a similar effect in the event of incomplete removal of butanol during the dry-down step, we decreased the proportion of methanol in the reconstitution medium to 50% (by volume).
Hydrolysis
of conjugates. Initial examinations of acid or base hydrolysis of the relatively stable alkyl-hydroxy conjugates of penbutolol indicated that other decompositions would proceed at rates comparable with those of conjugate hydrolysis. We thus explored in some detail conditions for enzymic hydrolysis. Glusulase, the crude glucuronidase/ sulfatase preparation from Helix pomatia, is commonly used. However, it contains a mixture of several compounds, some of which interfered with the present assay. Thus we examined several purified preparations, taking as a starting point in our experiments a previous report of success with short hydrolysis times (8). Overnight hydrolysis of two plasma pools and blank plasma at 45#{176}C with equivalent amounts of various enzymes showed that all of the purified enzymes gave much cleaner extracts than did Glusulase. Yields with types B-b and L-II were not comparable with those from Glusulase or G-0258, so we did not investigate the last two enzymes further. We then examined the time course of hydrolysis of penbutolol conjugates at short times with the remaining enzymes. At 45#{176}C in the presence of bisulfite, the reactions were nearly complete after 2 h. The ultimate yield of penbutolol for all three enzyme systems was comparable. The presence of methanol (100 milL) during the hydrolysis had little effect on these results. We were unable to quantify 4-hydroxypenbutolol in the experiments, because it was present in such low concentration in the plasma pool used. Apparently the hydrolysis yield peaked between 1 and 2 h, and in some cases declined thereafter.
An initial examination of the action of Glusulase
Three replicate hydrolyses were then done with each of the three enzyme systems on each of two plasma pools (Table 1) . The yield of 4-hydroxypenbutolol for all three enzymes is equivalent, reflecting the more rapid hydrolysis kinetics noted above. For penbutolol also, the results were consistent with those stated above. The addition of L-ll permits quantitative hydrolyses to be achieved in 2 h. If G-0258 or Glusulase is used alone, 95% yield is achieved after 2 h and complete hydrolysis after 3 h. To provide cleaner extracts, we chose (3-0258 over Glusulase. To minimize hydrolysis time and decrease the possibility of losses of 4-hydroxypenbutolol, we also included L-ll.
Because of the low cost of Glusulase relative to the purified enzymes, we tried to purify it by extraction. Aliquota of the preparation were adjusted to pH 4, 7, or 9.4; extracted with chloroform, ether, benzene, butyl chloride, or hexane, and used to hydrolyze portions of a pooled patient's urine and a blank urine. Extraction at pH 4 or 9.4 caused drastic losses of enzyme activity, and at pH 7 none of the solvents removed significant amounts of interferences. This approach was not pursued further.
Replicate hydrolyses of six urines for 2 h at 45 #{176}C in the presence of bisulfite, either by Glusulase or G-0258 plus L- 
Assay Characterization
We evaluated the linearity of response of the chromatographic system to drug concentrations by injecting various concentrations of penbutolol and 4-hydroxypenbutolol, dissolved in mobile phase, onto the chromatograph. The response to both compounds was linear over the whole range tested, 5 ng to 2 pg injected onto the column. The extraction recoveries for the procedures were estimated by using plasma that contained penbutolol (200 pg/L), 4-hydroxypenbutolol (100 jg/L), and propranolol as described earlier.
Analytical recoveries relative to nonextracted standards, after correction for the lack of transfer of all of the organic layer during the extraction, were between 75% and 95% for all three compounds, after either a single extraction or an extraction plus a wash step. The detection limits for the plasma assays were determined by the amount of background noise. Plasma interferences were not noted in either procedure. Although fresh plasma was used for preparation of standard curves, the use of either outdated plasmas from a local blood bank or a commercial serum preparation posed no problems when specifially tested for interferences. Detection limits were approximately 3 and 6 .tgfL of plasma for unconjugated 4-hydroxypenbutolol and penbutolol, respectively, and 6 and 12 ugfL for the total drugs in plasma. Detection limits for urine samples were approximately 50 jg of 4-hydroxypenbutolol and 20 pg penbutolol per liter.
Results of a study of the accuracy and precision of the assay for unconjugated drugs in plasma are summarized in Table 2 . Note that the overall relative standard deviations (CVs) were calculated from estimated within-and betweenday variabilities (11), not by simply calculating the CV of all the data together. Accuracy and precision for both compounds appear to be good over the range of the standard curves. This study, conductedwith drug-supplemented plasma, should be compared with the reproducibility results swnmarized in Table 3 . Plasma and urine pools were prepared from actual patients' specimens; then one aliquot was assayed each day, along with other samples. The reproducibility of the penbutolol assay results, either for free or total drug, is good and consistent with that in Table  2 . The precision of the plasma 4-hydroxypenbutolol assays was not as good, and variability was much higher than in We tested a series of drugs as potential assay interferents by injecting 500 ng of each onto the column. Those found not to interfere are listed in Table 4 . Physostigmine eluted between 4-hydroxypenbutolol and propranolol, but is normally administered only topically and should not interfere. Pergolide co-eluted with penbutolol, but typical concentrations of pergolide in plasma are <10 pgfL. Metoprolol eluted just before 4-hyroxypenbutolol,but typical concentrations of itare also <10 pgJL. Carazolol co-eluted with propranolol. Plasma standards containing both 4-hydroxypenbutolol and penbutolol appearedtobe stableforat least two months when stored at -20 #{176}C. On the other hand, we observed severe losses of 4-hydroxypenbutolol in patients' plasma samples after six weeks at -20 #{176}C. The loss appeared to be catastrophic rather than gradual, but we made no controlled study of this. Instability of 4-hydroxypropranolol has been previouslyreported (12) , and was assumed to be due to oxidative degradation.
To minimize this possibility we add antioxidants at each step in the extraction, leave the samples in the pH 9.4 buffer no longer than necessary, and omit tetrahydrofuran (commonly contaminated by peroxides) from the reconstitution medium.
Drug Metabolism and Concentrations in Blood
To identify the conjugates of penbutolol, we used a glucuronidase inhibitor, saccharic acid 1,4-lactone (9). The ratio of penbutolol concentrations obtained from incubations with glucuronidase plus inhibitor to concentrations of unconjugated penbutolol (no incubation with enzymes) for 16 plasma samples was 0.97 ± 0.13. The ratio of glucuronidasetreated to glucuronidase/inhibitor-treated samples was 19 ± 8. The data for 4-hydroxypenbutolol were more variable, but also showed no difference between samples not hydrolyzed and those hydrolyzed with inhibitor present. For a more detailed examination we used a single 4-to 12-h urine specimen for replicate hydrolyses with these and additional enzymes. Using G-0258 and L-ll, we detectedno penbutolol or 4-hydroxypenbutolol in incubations in which the inhibitor was included. Hydrolysis with a purified sulfatase preparation also yielded no drugs. Together, these data strongly suggest that penbutolol and 4-hydroxypenbutolol are nearly exclusively conjugated with glucuronic acid.
We noted the presence of several additional metabolites in plasma and urine specimens. Chromatograms from an early examination of hydrolyzed urine samples are depictedin five peaks that were not observed in chromatograms of the pre-dose urine. Penbutolol and 4-hydroxypenbutolol represent the largest areas, but a peak of nearly equivalent area (not seen in hexane/n-butanol extracts) elutedat a retention time of about 400 s. The area of this peak, seen in plasma extracts from all patients' samples examined, rose and fell as a function of time after dosing, consistent with the expected time course of a metabolite. In plasma it was present in lower concentrations than was 4-hydroxypenbutolol. We also saw a large amount (relative to 4-hydroxypenbutolol) of this presumed metabolite in nonhydrolyzed urines. We also detected conjugates of this metabolite in urine and plasma. The other two unidentified metabolites in Figure 4 are relatively minor. A third minor metabolite can be seen as a shoulder on the trailing side of the 4-hydroxypenbutolol peak in Figure 2B . 
Discussion
The liquid-chromatographic method reported here overcomes the specificity problems of previously reported nonchromatographic methods (2,3), whileprovidinggood sensitivity, convenience, and simultaneous determination of metabolites. It also offers several advantages relative to the other reported liquid-chromatographic method (6):much shorter hydrolysis time (2 vs. 48 h), avoidance of ion-pairing reagents through the use of a CN column, a two-step instead of a three-step extraction of the drugs after enzyme hydrolysis, and mild extraction conditions to minimize oxidative losses of 4-hydroxypenbutolol (pH 9.4 vs 13). Moreover, the previouslyreported method involvedchanging excitation and emission wavelengths during each chromatogram, which is quite inconvenient with anything other than a microprocessor-controlled fluorometer.
Finally, the sensitivity ofthe new method is superior to that reported previously.
The method described here has been successfully applied to two bioavailability studies, altogether involving 26 normal volunteers. In addition, multiple blood samples from more than 45 hypertensive patients receiving penbutolol daily have been assayed. With one exception, no significant interferences were noted in any of these studies. One case of inadvertant dosing with propranolol was clearly evident The concentrations reported here for blood aid urine are lower than those previously reported. The telectivity difference between the assays was borne out when we fluorometrically reassayed eight plasma samples iom each of two patients in the bioavailability study. The nethod used (from report #01-L43-0043-N of Hoechst) was timilar to those in the literature(2,3).
Regression analysis )f the data for unconjugated penbutolol in plasma gave the equation fluorescent (g/L) = (chromatographicx 1.29) + 6, confirming that additional species are being detected by ;imple fluorometric procedures.
Blood concentrations as letermined by thin-layer chromatography and gas chromaography (4,5) have been reported, but 4-hydroxypenbutolol was not determined by these methods.
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